Skip to main content

Table 4 Comparison between therapeutic response group and no-response group

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

  No-response group Response group P-value
Recipient sex, male 8/11 25/50 .171
Recipient age 43.6 ± 15.4 47.1 ± 11.7 .389
Donor sex, male 5/11 27/48 .517
Donor age 37.1 ± 9.0 37.1 ± 12.3 .994
Hematologic malignancy    .976
 AML 3 14  
 ALL 4 16  
 CML 0 1  
 NHL 0 2  
 MDS 4 17  
Donor type    .167
 Unrelated 3 25  
 Sibling 5 20  
 FMT 3 5  
HLA    .717
 full-match 7 36  
 mismatch 4 14  
Stem cell source    1.000
 PB 10 41  
 BM 1 7  
 Cord 0 2  
Time from HSCT to BOS diagnosis, days 407.0 (272.0–1533.0) 466.0 (274.3–833.3) .910
Acute GVHD 8/11 31/50 .731
Chronic GVHD (except lung)
 Skin 6/11 25/50 0.785
 Oral 7/11 35/50 0.726
 Eyes 9/11 27/50 0.106
 Liver 2/11 8/50 1.000
 Joint 0/11 3/50 1.000
Maximal score of chronic GVHD (except lung)a 1 (1–2) 1 (1–2) 0.227
Systemic steroid 8/11 25/50 .171
Steroid dose, mg (equivalent dose of prednisolone) 12.5 (4.4–16.3) 2.5 (0.0–15.0) .151
Tacrolimus 3/11 15/50 1.000
Cyclosporin 1/11 8/50 .683
Mycophenolate mofetil 5/11 13/50 .275
total CAT score, enroll 10.5 (6.8–16.0) 16.0 (10.0–20.0) .083
  1. aEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, GVHD graft-versus-host disease, CAT COPD assessment test